Last updated on May 2020

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

Brief description of study

This is a phase III, randomized, multicenter, open-label study which will be performed to evaluate efficacy and safety of oral Gepotidacin compared to intramuscular (IM) ceftriaxone plus oral azithromycin for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae in adolescent and adult subjects. In this study, subjects will be randomly assigned to receive either oral gepotidacin or IM ceftriaxone plus oral azithromycin. Approximately 600 subjects will be randomized to receive study treatment. The duration of the study will be approximately 21 days.

Clinical Study Identifier: NCT04010539

Find a site near you

Start Over

GSK Investigational Site

Darlinghurst, Australia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.